SOY ISOFLAVONE DISTRIBUTION IN BIOLOGICAL FLUIDS AS MARKERS OF PROSTATE EXPOSURE

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 研究表明，食用富含异黄酮类的大豆可以降低患前列腺癌的风险。被认为对这种影响负责的大豆成分是大豆异黄酮类(植物雌激素)。因此，目前正在流行病学和临床研究中研究异黄酮类化合物在前列腺癌预防中的可能作用。在这些研究中，准确估计个体中异黄酮类的暴露是极其重要的。鉴于饮食方法的不足，生物体液被认为是暴露于异黄酮类更可靠的指标。在设计这些研究时，研究人员通常假设血浆和尿液中的异黄酮浓度准确地反映了前列腺组织的暴露情况。然而，目前还没有关于这一假设的有效性的信息。因此，这项建议的主要目标是通过比较血和尿浓度与更直接的前列腺暴露测量来评估血浆和尿液异黄酮值的可靠性。为了实现这一目标，目前的研究将比较血浆和尿液中的异黄酮值与前列腺分泌物(EPS)中的异黄酮值，EPS是广泛接受的前列腺组织暴露的标志。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Research studies indicate that consumption of isoflavone-rich soy lowers prostate cancer risk. The soy components thought to be responsible for this effect are the soy isoflavones (phytoestrogens). As a result, isoflavones are currently being investigated in epidemiological and clinical studies for their possible roles in prostate cancer prevention. It is extremely important in these studies to have an accurate estimate of isoflavone exposure in individuals. Given the inadequacy of dietary methodolgies, biological fluids are considered more reliable indicators of exposure to isoflavones. In designing these studies, researchers have generally assumed that plasma and urinary isoflavone concentrations accurately reflect prostate tissue exposure. However, at this time, no information is available on the validity of this assumption. Thus, the main objective of this proposal is to evaluate the reliability of plasma and urinary isoflavone levels by comparing blood and urine concentrations to more direct measurements of prostate exposure. In order to accomplish this goal, the current study will compare isoflavone levels in plasma and urine with those in expressed prostate secretion (EPS), a widely accepted marker for prostate tissue exposure.